Sepracor reiterated by Smith Barney at hold

Sepracor Inc. was reiterated by Smith Barney Citigroup analyst Andrew Swanson at a hold rating following news of six of its drug patents being challenged by Breath Ltd., which is seeking approval for a generic version of Sepracor's Xopenex inhalation solution. Sepracor shares Thursday were up $0.71, or 1.35%, at $53.11 on volume of 2,377,582 shares versus the three-month running average of 1,810,620 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.